Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade B 124.05 0.06% 0.08
CELG closed up 0.06 percent on Friday, April 28, 2017, on approximately normal volume. It was able to find support at its 50 day moving average.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Flat
See historical CELG trend table...

Date Alert Name Type % Chg
Apr 28 50 DMA Support Bullish 0.00%
Apr 28 Bollinger Band Squeeze Range Contraction 0.00%
Apr 27 50 DMA Support Bullish 0.06%
Apr 27 Bollinger Band Squeeze Range Contraction 0.06%
Apr 26 Bollinger Band Squeeze Range Contraction -0.92%
Apr 26 Upper Bollinger Band Walk Other -0.92%
Apr 25 Bollinger Band Squeeze Range Contraction -1.17%
Apr 24 Crossed Above 50 DMA Bullish 0.73%
Apr 24 NR7 Range Contraction 0.73%
Apr 24 Bollinger Band Squeeze Range Contraction 0.73%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company’s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company’s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 127.64
52 Week Low 94.42
Average Volume 3,480,993
200-Day Moving Average 114.5022
50-Day Moving Average 123.6318
20-Day Moving Average 124.3155
10-Day Moving Average 123.842
Average True Range 1.8995
ADX 20.12
+DI 19.77
-DI: 23.07
Chandelier Exit (Long, 3 ATRs) 120.9615
Chandelier Exit (Short, 3 ATRs) 127.4085
Upper Bollinger Band 126.2685
Lower Bollinger Band 122.3625
Percent B (%b) 0.43
Bandwidth 0.03142